​

Faeth Therapeutics Stock (NASDAQ:FTH)

ForecastFinancialsChart
Faeth Therapeutics by TradingView

Previous Close

$10.65

52W Range

$7.45 - $42.14

50D Avg

$25.07

200D Avg

$25.43

Market Cap

$258.56M

Avg Vol (3M)

$484.22K

Beta

-0.30

Div Yield

-

FTH Company Profile

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Feb 04, 2021

Website

FTH Performance

FTH Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-22.29M$-31.66M$-37.06M
Net Income$-21.09M$-30.16M$-34.10M
EBITDA$-20.91M$-29.52M$-33.39M
Basic EPS$-16.72$-1.20$-1.22
Diluted EPS$-16.72$-1.20$-1.22

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PBYIPuma Biotechnology, Inc.
NUVBNuvation Bio Inc.
KZIAKazia Therapeutics Ltd ADR
BOLDBoundless Bio, Inc.
JANXJanux Therapeutics, Inc.
KURAKura Oncology, Inc.
RLAYRelay Therapeutics, Inc.
PRLDPrelude Therapeutics Incorporated
TNGXTango Therapeutics, Inc.
VSTMVerastem, Inc.